Essential tremor (ET) is one of the most common movement disorders worldwide, affecting an estimated seven million people in the United States alone. Characterized by involuntary rhythmic shaking, most often in the hands but sometimes in the head, voice, or legs, ET can significantly disrupt daily activities and reduce quality of life. Despite its prevalence, treatment options remain limited. Propranolol, the only FDA-approved pharmacotherapy, is not effective for all patients and carries side effects that may prevent its use in those with certain medical conditions. As a result, millions of patients continue to experience insufficient symptom control.
Recent developments, however, are offering new hope. Praxis Precision Medicines, a clinical-stage biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for ulixacaltamide, a small molecule inhibitor designed to target the neurological pathways underlying ET. This designation reflects the potential of ulixacaltamide to significantly improve treatment outcomes compared with currently available therapies.
Essential tremor is a neurological disorder that predominantly affects the upper limbs. Tremors associated with ET are rhythmic and involuntary, often worsening with age or over time. Although tremors may initially be mild, they frequently interfere with tasks such as writing, drinking from a cup, or using utensils. For some patients, the tremor can extend to other body parts, including the head, vocal cords, and legs, further complicating daily life.
Current pharmacological treatments are limited. Propranolol, a beta-blocker, is the only approved drug for ET. While some patients benefit from its use, many do not achieve sufficient symptom relief, and adverse effects can include fatigue, dizziness, and cardiovascular complications. Other medications, such as anticonvulsants or alternative beta-blockers, are used off-label but similarly face challenges of limited efficacy and tolerability. Consequently, surveys indicate that approximately 77% of patients feel their ET is inadequately controlled, and nearly 50% of those affected do not receive any treatment.
Ulixacaltamide is a highly selective small molecule designed to inhibit T-type calcium channels, key players in neuronal signaling pathways that contribute to tremor activity. By targeting these channels, ulixacaltamide aims to reduce abnormal burst firing in the cerebello-thalamo-cortical (CTC) circuit, which is believed to be a primary driver of tremor in ET.
Praxis’ clinical program, known as Essential3, involved two pivotal Phase 3 trials that evaluated the efficacy and safety of ulixacaltamide in patients with ET. The trials demonstrated promising results, showing improvements in tremor severity and daily function, which ultimately supported the FDA’s decision to grant Breakthrough Therapy Designation.
The BTD is significant because it allows for expedited development and regulatory review of therapies intended to treat serious or life-threatening conditions. Preliminary clinical evidence suggests that ulixacaltamide may offer substantial improvement over existing treatments, providing a potentially transformative option for patients who previously had limited choices.
The potential approval of ulixacaltamide could transform the treatment landscape for ET. With over two million patients currently seeking effective therapy, the introduction of a highly selective and targeted treatment option is a crucial step forward. Ulixacaltamide could help reduce tremor severity, improve motor function, and enhance overall quality of life for individuals living with this debilitating condition.
In addition to clinical benefits, the availability of a well-tolerated and effective therapy may reduce the burden on caregivers and healthcare providers, while addressing the unmet needs of a large segment of the ET population. For patients whose daily activities are disrupted by tremor, the ability to regain control over basic tasks could have profound psychosocial and functional benefits.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on translating genetic insights into therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company leverages its proprietary Cerebrum small molecule platform, which includes ulixacaltamide as its most advanced program, alongside an antisense oligonucleotide (ASO) platform called Solidus.
The Cerebrum platform allows Praxis to identify and target specific neural circuits implicated in movement disorders and epilepsy, creating opportunities for highly targeted therapies that address the underlying biology of the disease rather than merely alleviating symptoms. This approach represents a shift toward precision medicine in neurology, offering hope for patients with conditions previously considered difficult to treat.
Following the granting of Breakthrough Therapy Designation, Praxis completed a pre-New Drug Application (NDA) meeting with the FDA in December 2025. The meeting included both written feedback and an in-person consultation to align on the content and structure of the NDA submission. The company plans to submit the ulixacaltamide NDA in early 2026, marking a significant milestone in the potential availability of the therapy to patients.
Breakthrough Therapy Designation not only accelerates the review process but also provides increased interaction with the FDA, allowing for timely feedback and guidance on clinical development. This regulatory support is essential for bringing new therapies to market more efficiently while maintaining rigorous standards of safety and efficacy.
Essential tremor represents a multi-billion dollar commercial opportunity, given the large number of affected individuals and the lack of effective treatment options. Surveys indicate a substantial gap between patient need and available therapies, highlighting the importance of developing innovative treatments.
With propranolol as the only approved therapy, the market is underserved, and patients frequently seek alternative or off-label treatments with limited efficacy. The introduction of ulixacaltamide has the potential to address this unmet need, offering a targeted, effective, and tolerable option for millions of patients.
The FDA’s Breakthrough Therapy Designation for ulixacaltamide marks an exciting development in the treatment of essential tremor. By targeting the underlying neuronal mechanisms associated with tremor, this therapy offers hope for improved symptom control and enhanced quality of life. As Praxis prepares to submit its NDA, patients, caregivers, and healthcare providers alike are watching closely, anticipating a new era of precision medicine for movement disorders.
For individuals living with ET, the development of ulixacaltamide could represent more than just a new drug. It offers the potential to reclaim daily functions, participate more fully in life, and reduce the social and psychological burdens of living with tremor.
Praxis Precision Medicines, “Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor,” Globe Newswire, December 29, 2025.
This blog is for educational and informational purposes only and does not constitute medical advice. Readers should not make decisions about medications or treatments based solely on this information. Consult a licensed healthcare professional for diagnosis, treatment, and guidance specific to your medical condition.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.